Future Management of Uveal Melanoma

Source: OncLive, August 2021

Richard D. Carvajal, MD: Marlana, this has been a great conversation. Let’s close with future directions. Where are we going with tebentafusp? What are the next trials we must do and the next set of questions we have to answer?

Marlana M. Orloff, MD: Teasing out why there is still such a great response in patients whose best overall response is progressive disease is an important question, because again to your comment, can we stop some treatment in these patients?

READ THE ORIGINAL FULL ARTICLE